Journal article

The Use of Optimal Treatment for DLBCL Is Improving in All Age Groups and Is a Key Factor in Overall Survival, but Non-Clinical Factors Influence Treatment

Nicole Wong Doo, Victoria M White, Kara Martin, Julie K Bassett, H Miles Prince, Simon J Harrison, Michael Jefford, Ingrid Winship, Jeremy L Millar, Roger L Milne, John F Seymour, Graham G Giles

Cancers | MDPI | Published : 2019

Abstract

INTRODUCTION: Diffuse large B cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma for which a cure is usually the therapeutic goal of optimal treatment. Using a large population-based cohort we sought to examine the factors associated with optimal DLBCL treatment and survival. METHODS: DLBCL cases were identified through the population-based Victorian Cancer Registry, capturing new diagnoses for two time periods: 2008-2009 and 2012-2013. Treatment was pre-emptively classified as 'optimal' or 'suboptimal', according to compliance with current treatment guidelines. Univariable and multivariable logistic regression models were fitted to determine factors associated with treatmen..

View full abstract

Grants

Awarded by Translational Cancer Research Funding grant from the Victorian Cancer Agency


Funding Acknowledgements

This work was funded by a Translational Cancer Research Funding grant from the Victorian Cancer Agency (#EOI09_36).